研报掘金丨国泰君安:维持东鹏饮料“增持”评级 看好果之茶单品逐渐放量
国泰君安研报指出,东鹏饮料(605499.SH)果之茶迅速放量。公司果之茶新品今年2月上市,零售价5元/瓶,有西柚、柠檬、蜜桃三款口味,主要对标康师傅统一及元气森林的冰茶系列,考虑到茶饮料行业空间大(根据欧睿数据,2024年销售规模1364亿元),东鹏果之茶质价比及渠道推力突出,同时用户画像与特饮有很大重叠(年轻人为主),因此我们看好果之茶单品逐渐放量,有望成为特饮及补水啦之后的第三增长曲线。3月动销改善,旺季延续高增趋势无虞。此外,公司发布公吿,拟发行H股股票并在香港联合交易所有限公司主板挂牌上市,认为港股上市有望助力公司推进全球化战略的落地。维持“增持”评级及目标价319元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.